Cassava Sciences receives FDA request for more information on epilepsy trial

Cassava Sciences has received a request from the FDA for additional information regarding its ongoing epilepsy trial. This request indicates that the regulatory body is seeking further clarification or data before proceeding with the evaluation of the trial results.

This development is significant for Cassava Sciences as it may impact the timeline for potential approval of its epilepsy treatment. The need for more information could delay the trial process, affecting investor confidence and the company's market position in the pharmaceutical sector.